Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis | Zendy

Michael E. Wechsler | Zendy; Praveen Akuthota | Zendy; David Jayne | Zendy; Paneez Khoury | Zendy; Amy D. Klion | Zendy; Carol A. Langford | Zendy; Peter A. Merkel | Zendy; Frank Moosig | Zendy; Ulrich Specks | Zendy; María C. Cid | Zendy; Raashid Luqmani | Zendy; Judith C. Brown | Zendy; Stephen Mallett | Zendy; Richard Philipson | Zendy; Steve Yancey | Zendy; Jonathan Steinfeld | Zendy; Peter F. Weller | Zendy; Gerald J. Gleich | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

Author(s) -

Michael E. Wechsler,

Praveen Akuthota,

David Jayne,

Paneez Khoury,

Amy D. Klion,

Carol A. Langford,

Peter A. Merkel,

Frank Moosig,

Ulrich Specks,

María C. Cid,

Raashid Luqmani,

Judith C. Brown,

Stephen Mallett,

Richard Philipson,

Steve Yancey,

Jonathan Steinfeld,

Peter F. Weller,

Gerald J. Gleich

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1702079

Subject(s) - mepolizumab , medicine , granulomatosis with polyangiitis , gastroenterology , placebo , randomization , confidence interval , odds ratio , prednisone , surgery , vasculitis , randomized controlled trial , eosinophil , pathology , asthma , disease , alternative medicine

Eosinophilic granulomatosis with polyangiitis is an eosinophilic vasculitis. Mepolizumab, an anti-interleukin-5 monoclonal antibody, reduces blood eosinophil counts and may have value in the treatment of eosinophilic granulomatosis with polyangiitis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research